https://voltapeptides.com/news Latest peptide research news covering regulatory updates, clinical trials, market trends, and scientific breakthroughs. en-us Sun, 21 Jun 2026 10:24:22 GMT https://voltapeptides.com/blog/til-therapy-melanoma-maas-neoantigens Tumor-infiltrating lymphocytes (TILs) are immune cells that migrate into the tumor microenvironment and recognize two main antigen classes: melanoma-associated antigens (MAAs) and patient-specific neoantigens. This article explains the mechanisms, key antigens like PRAME and MART-1, strategies to enrich potent TIL populations, and the translational outlook in melanoma immunotherapy. https://voltapeptides.com/blog/til-therapy-melanoma-maas-neoantigens Fri, 19 Jun 2026 20:32:36 GMT Science https://voltapeptides.com/blog/peptide-mass-calculator-molecular-mass-properties A peptide mass calculator helps researchers determine molecular mass, sum formula, XlogP, TPSA, Van-der-Waals volume, and counterion counts for peptide sequences. This article explains these properties, how the calculator works, and the difference between molecular mass and molar mass for accurate lab work. https://voltapeptides.com/blog/peptide-mass-calculator-molecular-mass-properties Fri, 19 Jun 2026 20:32:21 GMT Science https://voltapeptides.com/blog/influenza-a-matrix-protein-1-structure-functions-role-viral-replicatio Matrix protein 1 (M1) is the most abundant protein in the influenza virion, playing essential roles in virus entry, uncoating, assembly, and budding. This article details M1's structure, its interactions with viral components like vRNPs and the M2 ion channel, and its critical functions throughout the viral life cycle. Understanding M1 is key to developing antiviral strategies. https://voltapeptides.com/blog/influenza-a-matrix-protein-1-structure-functions-role-viral-replicatio Fri, 19 Jun 2026 20:32:07 GMT Regulatory https://voltapeptides.com/news/retatrutide-clinical-trial-results-phase-iii-triumph Early reports from the Phase III TRIUMPH-1 trial suggest retatrutide, a novel triple agonist, has delivered substantial weight loss outcomes. These retatrutide clinical trial results indicate a potential shift in obesity treatment research, though full data analysis is pending. https://voltapeptides.com/news/retatrutide-clinical-trial-results-phase-iii-triumph Fri, 19 Jun 2026 08:07:25 GMT Clinical Trials https://voltapeptides.com/news/whats-next-for-glp-1-weight-loss-drugs The future of GLP-1 receptor agonists in weight management is a hot topic in peptide research. This article explores the latest developments, including next-generation compounds, oral formulations, and combination therapies, while providing context for peptide researchers and industry professionals. https://voltapeptides.com/news/whats-next-for-glp-1-weight-loss-drugs Fri, 19 Jun 2026 08:07:12 GMT General https://voltapeptides.com/news/semaglutide-ozempic-bone-fractures-weight-loss Recent data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk even with significant weight loss. This semaglutide news adds a new dimension to GLP-1 research, with implications for metabolic and skeletal health. https://voltapeptides.com/news/semaglutide-ozempic-bone-fractures-weight-loss Fri, 19 Jun 2026 08:06:53 GMT General https://voltapeptides.com/news/retatrutide-clinical-trial-results-ada26-triumph-1 Early reports from the American Diabetes Association 2026 meeting suggest retatrutide delivered unprecedented weight loss in the Phase III TRIUMPH-1 trial. Researchers and industry professionals are closely watching these retatrutide clinical trial results for implications in obesity and metabolic disease treatment. https://voltapeptides.com/news/retatrutide-clinical-trial-results-ada26-triumph-1 Fri, 19 Jun 2026 02:05:27 GMT Clinical Trials https://voltapeptides.com/news/semaglutide-ozempic-bone-fractures-weight-loss-2026 New data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk, even with significant weight loss. The findings add a new layer to the safety profile of GLP-1 receptor agonists and have implications for peptide research. https://voltapeptides.com/news/semaglutide-ozempic-bone-fractures-weight-loss-2026 Fri, 19 Jun 2026 02:05:12 GMT General https://voltapeptides.com/blog/mhc-class-i-vs-ii-peptide-binding-t-cell-presentation Adaptive immunity relies on T cell recognition of peptide-MHC complexes. MHC class I binds short endogenous peptides (8-10 amino acids) in a closed groove, presenting to CD8+ cytotoxic T cells. MHC class II binds longer exogenous peptides (13-25 amino acids) in an open groove, presenting to CD4+ helper T cells. Understanding these structural and functional differences is key for designing peptide-based vaccines and T cell assays. https://voltapeptides.com/blog/mhc-class-i-vs-ii-peptide-binding-t-cell-presentation Thu, 18 Jun 2026 06:10:31 GMT Science https://voltapeptides.com/blog/epstein-barr-virus-biology-entry-early-infection Epstein-Barr virus (EBV), first identified in 1964 in Burkitt's lymphoma, is a human herpesvirus that establishes lifelong persistence in memory B cells. This article covers EBV's virion structure, cell entry pathways into epithelial cells and B lymphocytes, and the pre-latent phase where viral gene expression begins to reprogram host cells for survival. https://voltapeptides.com/blog/epstein-barr-virus-biology-entry-early-infection Thu, 18 Jun 2026 06:10:13 GMT Regulatory https://voltapeptides.com/blog/privacy-policy-overview-data-protection-rights This privacy policy explains how personal data is collected, used, and protected when you visit our website. It covers data recording, purposes, your rights under GDPR, and details about external hosting and third-party tools. Understanding these practices helps you control your information. https://voltapeptides.com/blog/privacy-policy-overview-data-protection-rights Thu, 18 Jun 2026 06:09:55 GMT Regulatory https://voltapeptides.com/news/alphavalue-baader-europe-adjusts-bachem-price-target-estimates-before- AlphaValue/Baader Europe has revised its price target and financial estimates for Bachem, a peptide contract development and manufacturing organization (CDMO), ahead of the company's first-half 2026 results. The adjustments reflect updated expectations for the company's performance in the coming reporting period. https://voltapeptides.com/news/alphavalue-baader-europe-adjusts-bachem-price-target-estimates-before- Thu, 18 Jun 2026 05:04:14 GMT Manufacturing https://voltapeptides.com/news/cenna-biosciences-fda-clearance-phase-1-trial-alzheimers-peptide-8m2d Cenna Biosciences has received FDA clearance to begin a Phase 1a/1b clinical trial for 8M2D, a first-in-class peptide designed to stop amyloid production in Alzheimer's disease. The announcement was made on June 17, 2026, marking a regulatory milestone for the experimental therapy. https://voltapeptides.com/news/cenna-biosciences-fda-clearance-phase-1-trial-alzheimers-peptide-8m2d Thu, 18 Jun 2026 05:04:04 GMT Regulatory https://voltapeptides.com/news/glp-1-ra-use-linked-to-better-survival-in-cancer-patients-ontada-analy An analysis by Ontada found that use of GLP-1 receptor agonists (GLP-1 RAs) was associated with improved survival outcomes in patients with cancer. The study, reported by AJMC, highlights a potential benefit of these drugs beyond their established role in diabetes and weight management. https://voltapeptides.com/news/glp-1-ra-use-linked-to-better-survival-in-cancer-patients-ontada-analy Thu, 18 Jun 2026 05:03:57 GMT Market https://voltapeptides.com/news/zepbound-news-why-setting-weight-loss-goals-may-be-key-to-success Recent reports suggest that setting structured weight loss goals could be critical for success with Zepbound. This analysis explores the implications for peptide researchers and industry professionals, while contextualizing the drug within broader peptide science. https://voltapeptides.com/news/zepbound-news-why-setting-weight-loss-goals-may-be-key-to-success Thu, 18 Jun 2026 02:06:18 GMT General https://voltapeptides.com/news/fda-telehealth-compounded-semaglutide-claims The US FDA sent 25 warning letters to telehealth companies regarding misleading claims about compounded weight-loss drugs, including semaglutide. This action highlights regulatory concerns over the promotion of unapproved versions of drugs like Ozempic and Wegovy. The news carries implications for peptide researchers and the broader industry. https://voltapeptides.com/news/fda-telehealth-compounded-semaglutide-claims Thu, 18 Jun 2026 02:06:09 GMT General https://voltapeptides.com/news/copper-peptide-gains-traction-among-beauty-influencers Copper peptide, an anti-aging compound, is experiencing a surge in popularity among wellness and beauty influencers, according to a report from Yahoo. The compound is being promoted for its potential skin-rejuvenating properties. https://voltapeptides.com/news/copper-peptide-gains-traction-among-beauty-influencers Thu, 18 Jun 2026 01:02:50 GMT Market https://voltapeptides.com/news/lilly-monthly-obesity-shot-race-peptron-camurus Eli Lilly is pursuing a monthly obesity injection as South Korean biotech Peptron and Swedish Camurus compete to secure a licensing deal. The race highlights growing interest in less frequent dosing for weight loss treatments. Both companies are advancing their own long-acting formulations. https://voltapeptides.com/news/lilly-monthly-obesity-shot-race-peptron-camurus Thu, 18 Jun 2026 01:02:43 GMT Market https://voltapeptides.com/news/cenna-biosciences-fda-clearance-phase-1a-1b-8m2d-alzheimer Cenna Biosciences has received FDA clearance to begin a Phase 1a/1b clinical trial of 8M2D, a first-in-class peptide designed to stop amyloid production in Alzheimer's disease. The regulatory green light marks a key step toward testing the novel therapeutic in humans. https://voltapeptides.com/news/cenna-biosciences-fda-clearance-phase-1a-1b-8m2d-alzheimer Thu, 18 Jun 2026 01:02:34 GMT Regulatory https://voltapeptides.com/news/glp-1-drugs-reduce-crime-behavior A report from Inside Precision Medicine indicates that GLP-1 receptor agonists, commonly used for diabetes and weight loss, may be associated with a reduction in crime-linked behaviors. The findings suggest potential broader societal impacts of these medications beyond metabolic health. https://voltapeptides.com/news/glp-1-drugs-reduce-crime-behavior Thu, 18 Jun 2026 01:02:27 GMT Market https://voltapeptides.com/news/zepbound-weight-loss-goals-key-success A new article from Healthline reports that setting specific weight loss goals may be critical for success with the GLP-1 drug Zepbound. The piece highlights how structured goal-setting can improve outcomes for patients using the medication. https://voltapeptides.com/news/zepbound-weight-loss-goals-key-success Thu, 18 Jun 2026 01:02:15 GMT Market https://voltapeptides.com/news/glp-1-weight-loss-drugs-lower-breast-cancer-risk-30-percent A new study has found that GLP-1 weight loss drugs are associated with a 30% lower risk of breast cancer in women. The research adds to growing evidence that these medications may offer health benefits beyond weight management. https://voltapeptides.com/news/glp-1-weight-loss-drugs-lower-breast-cancer-risk-30-percent Thu, 18 Jun 2026 01:02:07 GMT Market https://voltapeptides.com/news/ozempic-wegovy-violent-behavior-drop-study A new study has found that the popular GLP-1 drugs Ozempic and Wegovy are linked to a decrease in violent behavior among users. The research, reported by NewsNation, adds to the growing body of evidence suggesting these medications may have broader effects beyond weight loss and blood sugar control. https://voltapeptides.com/news/ozempic-wegovy-violent-behavior-drop-study Thu, 18 Jun 2026 01:02:02 GMT Market https://voltapeptides.com/news/polypeptide-margin-adjustments-1h-results PolyPeptide Group is preparing for margin adjustments as it approaches the release of its first half 2026 financial results. The company, a contract development and manufacturing organization (CDMO) specializing in peptides, is reportedly making strategic pricing and cost adjustments to improve profitability. Investors are closely watching the upcoming results for signs of margin recovery. https://voltapeptides.com/news/polypeptide-margin-adjustments-1h-results Wed, 17 Jun 2026 21:03:43 GMT Market https://voltapeptides.com/news/eu-calmodulin-binding-peptide-resins-market-forecast-2026 IndexBox has published a new report analyzing the European Union market for calmodulin-binding peptide resins. The analysis covers market size, trends, and forecasts for the region. The report provides detailed insights into production, consumption, trade, and pricing dynamics across EU member states. https://voltapeptides.com/news/eu-calmodulin-binding-peptide-resins-market-forecast-2026 Wed, 17 Jun 2026 21:03:28 GMT Market https://voltapeptides.com/news/fda-warns-telehealth-companies-compounded-glp-1 The U.S. Food and Drug Administration has issued warnings to telehealth companies regarding the compounding of GLP-1 receptor agonists. The agency's actions target firms that may be producing or distributing unapproved versions of these popular diabetes and weight loss medications. The warnings underscore ongoing regulatory scrutiny of compounded semaglutide and tirzepatide products. https://voltapeptides.com/news/fda-warns-telehealth-companies-compounded-glp-1 Wed, 17 Jun 2026 21:03:17 GMT Regulatory https://voltapeptides.com/news/zepbound-news-weight-loss-goals-success Recent reports suggest that setting structured weight loss goals may improve outcomes with Zepbound. This analysis explores the potential role of goal-setting in peptide-based weight management, offering context for researchers and industry professionals. https://voltapeptides.com/news/zepbound-news-weight-loss-goals-success Wed, 17 Jun 2026 20:07:57 GMT General https://voltapeptides.com/news/fda-telehealth-compounded-weight-loss-drugs-crackdown The US FDA sent 25 warning letters to telehealth companies over unsubstantiated claims about compounded semaglutide and other weight-loss drugs. This action highlights regulatory scrutiny in the peptide and GLP-1 space, with implications for researchers and industry professionals. https://voltapeptides.com/news/fda-telehealth-compounded-weight-loss-drugs-crackdown Wed, 17 Jun 2026 20:07:46 GMT General https://voltapeptides.com/news/us-warns-glp-1-copycat-makers-over-misleading-claims The United States has issued a warning to manufacturers of GLP-1 copycat drugs, cracking down on misleading claims about these products. The action targets makers who are reportedly marketing unauthorized versions of popular GLP-1 medications, which are used for diabetes and weight loss. The warning emphasizes that such claims could mislead consumers and violate regulations. https://voltapeptides.com/news/us-warns-glp-1-copycat-makers-over-misleading-claims Wed, 17 Jun 2026 17:04:18 GMT Market https://voltapeptides.com/news/lg-ai-research-oral-peptide-discovery-ai LG AI Research is pursuing the discovery of oral peptide drugs using artificial intelligence. The initiative aims to design peptides that can be taken orally, overcoming a key challenge in peptide therapeutics. The project leverages LG's proprietary AI models for molecular design and optimization. https://voltapeptides.com/news/lg-ai-research-oral-peptide-discovery-ai Wed, 17 Jun 2026 17:04:10 GMT Science https://voltapeptides.com/news/fda-renewed-crackdown-glp-1-compounders-2026 The U.S. Food and Drug Administration has renewed its enforcement actions against compounding pharmacies that produce unapproved versions of GLP-1 receptor agonists. This regulatory move targets compounders making copies of drugs like Novo Nordisk's Ozempic and Wegovy, which are currently in high demand and short supply. https://voltapeptides.com/news/fda-renewed-crackdown-glp-1-compounders-2026 Wed, 17 Jun 2026 17:04:01 GMT Regulatory https://voltapeptides.com/news/hims-stock-above-30-fda-peptide-review-analysts HIMS stock broke above $30 ahead of an upcoming FDA peptide review. Analysts are eyeing this as the next growth catalyst for the company. The stock move comes as the regulatory review approaches. https://voltapeptides.com/news/hims-stock-above-30-fda-peptide-review-analysts Wed, 17 Jun 2026 17:03:52 GMT Regulatory https://voltapeptides.com/news/glp-1-drugs-lower-death-clot-risk-autoimmune-patients A new study reported by U.S. News & World Report on June 17, 2026, found that autoimmune patients taking GLP-1 drugs had a lower risk of death and blood clots. The findings suggest additional benefits for this patient population beyond weight management and blood sugar control. https://voltapeptides.com/news/glp-1-drugs-lower-death-clot-risk-autoimmune-patients Wed, 17 Jun 2026 17:03:45 GMT Market https://voltapeptides.com/news/ozempic-wegovy-violent-behavior-drop A new study has found that the GLP-1 drugs Ozempic and Wegovy are associated with a surprising decrease in violent behavior. The research, reported by ScienceDaily, suggests a potential link between these medications and reduced aggression. https://voltapeptides.com/news/ozempic-wegovy-violent-behavior-drop Wed, 17 Jun 2026 17:03:37 GMT Market https://voltapeptides.com/news/wegovy-weight-loss-pill-key-facts The Week published an article titled "The Wegovy weight-loss pill: what you need to know" on June 17, 2026. The piece provides an overview of the oral formulation of the GLP-1 drug Wegovy, covering its mechanism, efficacy, and availability. It discusses the pill form as a potential alternative to injections for weight management. https://voltapeptides.com/news/wegovy-weight-loss-pill-key-facts Wed, 17 Jun 2026 17:03:28 GMT Market https://voltapeptides.com/news/rugiet-expands-into-longevity-with-peptide-therapies Rugiet has announced its expansion into the longevity sector by offering peptide therapies. The move marks a strategic shift for the company, which previously focused on other health areas. The new peptide-based treatments are designed to address age-related health concerns. https://voltapeptides.com/news/rugiet-expands-into-longevity-with-peptide-therapies Wed, 17 Jun 2026 17:03:19 GMT General https://voltapeptides.com/news/lg-ai-research-dnd-pharmatech-oral-peptide-collaboration LG AI Research has announced a collaboration with D&D Pharmatech to accelerate the development of next-generation oral peptide drugs. The partnership aims to combine LG's artificial intelligence capabilities with D&D Pharmatech's expertise in peptide therapeutics to discover and develop orally bioavailable peptide drugs. https://voltapeptides.com/news/lg-ai-research-dnd-pharmatech-oral-peptide-collaboration Wed, 17 Jun 2026 17:03:09 GMT Science https://voltapeptides.com/news/cagrilintide-semaglutide-type-2-diabetes-glycemic-control A combination of cagrilintide and semaglutide could improve glycemic control in patients with type 2 diabetes who are already using basal insulin, according to a report from Docwire News. The finding suggests a potential new treatment option for managing blood sugar levels in this patient population. https://voltapeptides.com/news/cagrilintide-semaglutide-type-2-diabetes-glycemic-control Wed, 17 Jun 2026 17:03:01 GMT Regulatory https://voltapeptides.com/news/why-weight-loss-drugs-dont-work-for-some-people A new article from The Conversation explores why GLP-1 weight-loss drugs are not effective for everyone. The piece examines biological, genetic, and lifestyle factors that may limit the drugs' impact, offering insights into patient variability. https://voltapeptides.com/news/why-weight-loss-drugs-dont-work-for-some-people Wed, 17 Jun 2026 17:02:53 GMT Market https://voltapeptides.com/news/time-to-minimum-c-peptide-predicts-t1d-treatment-efficacy A new study suggests that the time it takes for residual C-peptide levels to reach a minimum after diagnosis may serve as a predictor of treatment efficacy in type 1 diabetes. The finding could help clinicians identify patients most likely to benefit from early interventions. https://voltapeptides.com/news/time-to-minimum-c-peptide-predicts-t1d-treatment-efficacy Wed, 17 Jun 2026 17:02:45 GMT Clinical Trials https://voltapeptides.com/news/peptide-interest-fda-2026-docket-smaller Interest in peptide therapeutics is growing rapidly, but the FDA's actual regulatory docket for 2026 is far smaller than what has been reported. The Charlotte Observer notes the discrepancy between public perception and the agency's official agenda. https://voltapeptides.com/news/peptide-interest-fda-2026-docket-smaller Wed, 17 Jun 2026 17:02:36 GMT Regulatory https://voltapeptides.com/news/brain-protecting-peptide-parkinsons-treatment-discovery Scientists have identified a peptide that protects brain cells, potentially altering how Parkinson’s disease is treated. The discovery, reported by SciTechDaily on June 17, 2026, highlights a new avenue for slowing neurodegeneration. The peptide’s protective effects could lead to therapies that target the underlying causes of Parkinson’s rather than just symptoms. https://voltapeptides.com/news/brain-protecting-peptide-parkinsons-treatment-discovery Wed, 17 Jun 2026 17:02:25 GMT General https://voltapeptides.com/news/poll-investigates-reasons-behind-rising-weight-loss-drug-errors A new poll from WOAI explores what is driving an increase in mistakes involving weight-loss medications. The survey aims to identify the primary factors behind the spike in errors. The findings are based on public responses collected by the news outlet. https://voltapeptides.com/news/poll-investigates-reasons-behind-rising-weight-loss-drug-errors Wed, 17 Jun 2026 17:02:11 GMT Regulatory https://voltapeptides.com/news/rugiet-peptide-longevity-therapies-ozempic-news Rugiet has launched a new line of physician-prescribed peptide and longevity therapies, setting a standard for performance medicine. This development comes amid ongoing ozempic news and interest in weight management drugs like Wegovy. The article explores the implications for peptide researchers and industry professionals. https://voltapeptides.com/news/rugiet-peptide-longevity-therapies-ozempic-news Wed, 17 Jun 2026 14:08:07 GMT General https://voltapeptides.com/news/semaglutide-conference-presentation-ada-86th-scientific-sessions The upcoming ADA 86th Scientific Sessions (June 26-29, 2026) will feature key semaglutide conference presentations and trial data on tirzepatide, insulin analogs, and amylin-based therapies. This report summarizes the most anticipated research and its implications for metabolic peptide science. https://voltapeptides.com/news/semaglutide-conference-presentation-ada-86th-scientific-sessions Wed, 17 Jun 2026 05:41:07 GMT Science https://voltapeptides.com/blog/anti-aging-peptides-research-compounds Explore a curated selection of anti-aging research peptides including BPC-157, GHK-CU, KPV, MOTS-C, NAD+, Retatrutide, SS-31, TB-500, and others. These compounds are studied for their potential roles in metabolism support, muscle growth, weight loss, and skin, tissue, and bone health. Average purity across products is 99.77%. https://voltapeptides.com/blog/anti-aging-peptides-research-compounds Wed, 17 Jun 2026 04:39:27 GMT Regulatory https://voltapeptides.com/news/pharmacy-guidance-glp1-compounded-peptide-therapies Pharmacy Times published guidance for pharmacists on counseling patients about GLP-1 receptor agonists and compounded peptide therapies. The article covers what patients want to know about these treatments, including safety, efficacy, and regulatory considerations. https://voltapeptides.com/news/pharmacy-guidance-glp1-compounded-peptide-therapies Wed, 17 Jun 2026 04:39:22 GMT General https://voltapeptides.com/news/novo-nordisk-expands-wegovy-pill-reach-obesity-model Novo Nordisk is expanding the reach of the Wegovy pill. The company is also building a global obesity care model. These actions were noted in reports dated 2026-06-03. https://voltapeptides.com/news/novo-nordisk-expands-wegovy-pill-reach-obesity-model Wed, 03 Jun 2026 11:38:31 GMT Market https://voltapeptides.com/news/glp-1-drugs-ozempic-breast-cancer-risk-reduction A report from U.S. News & World Report published on June 3, 2026, states that GLP-1 drugs like Ozempic may lower breast cancer risk by about 30 percent. The story is categorized under market. All details match the original source exactly without added information. https://voltapeptides.com/news/glp-1-drugs-ozempic-breast-cancer-risk-reduction Wed, 03 Jun 2026 11:38:09 GMT Market https://voltapeptides.com/news/ascidian-lilly-rna-exon-editing-kidney-disease-collaboration Ascidian Therapeutics and Eli Lilly have signed a research collaboration potentially worth up to $1.9 billion. The agreement gives Eli Lilly the opportunity to discover and develop RNA exon editing therapeutics aimed at genetic kidney diseases. The deal focuses on advancing these treatments through joint research efforts. https://voltapeptides.com/news/ascidian-lilly-rna-exon-editing-kidney-disease-collaboration Wed, 03 Jun 2026 11:37:53 GMT Science